93440

STIC-Biotech/ChemLib

From: Turner, Sharon
Sent: Wednesday, May 07, 2003 11:25 AM
To: STIC-Biotech/ChemLib
Subject: 09092297

Please search Interference files

Standard and Oligomer search SEQ ID NO's 5 and 17

Please print first 50 hits of each.

priority 08/869,579 fd 6-5-97
dilbert

Thanks,
Sharon L. Turner, Ph.D.
USPTO
CM1-10B09
Mailroom 10B19
Biotechnology GAU 1647
(703) 308-0056

Point of Contact:
Toby Port
Technical Info. Specialist
CM1 6A04
703-308-3534

ipd 6-5-98
priority denied
for "N"

Muni.
Abbott

09/673 891 12-13-00 4-15-99 post

60/070 771 1-9-98 Smyth

	TYPE OF SEARCH:	VENDOR/COST (where applic.)
Searcher:_____	NA Sequences:_____	STN:_____
Phone:_____	AA Sequences:_____	DIALOG:_____
Location:_____	Structures:_____	Questel/Orbit:_____
Date Picked Up: 5/8	Bibliographic:_____	DRLink:_____
Date Completed: 5/16	Litigation:_____	Lexis/Nexis:_____
Searcher Prep/Review:_____	Full text:_____	Sequence Sys.:_____
Clerical:_____	Patent Family:_____	WWW/Internet:_____
Online time:_____	Other:_____	Other (specify):_____

L20 ANSWER 9 OF 75 CAPLUS COPYRIGHT 1999 ACS
AN 1999:64978 CAPLUS
DN 130:137833
TI A marker gene for urinary tract disease and cancer and its diagnostic, therapeutic, and prognostic uses
IN **Billing-Medel, Patricia A.**; **Cohen, Maurice**; **Colpitts, Tracey L.**; **Friedman, Paula N.**; **Gordon, Julian**; **Granados, Edward N.**; **Hodges, Steven C.**; **Klass, Michael R.**; Kratochvil, Jon D.; **Russell, John C.**; **Stroupe, Stephen D.**; Yu, Hong
PA Abbott Laboratories, USA
SO PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9902734	A1	19990121	WO 98-US14210	19980708
	W: CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	US 97-889866		19970708		

AB A set of contiguous and partially overlapping cDNA sequences from a gene designated BL210 that is transcribed in the urinary tract, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or detg. the predisposition of an individual to diseases and conditions of the urinary tract, such as bladder cancer. Antibodies specific for the BL210-encoded protein, and agonists or inhibitors which prevent action of the tissue-specific BL210 polypeptide, that may be useful for the therapeutic treatment of urinary tract diseases, tumors or metastases are also disclosed. The gene was identified as an EST cluster expressed in urinary tract tissue. Sequences were assembled into a full-length cDNA and a consensus sequence derived. Antigenic peptides derived from the consensus sequence were synthesized and used to immunize rabbits.

L20 ANSWER 15 OF 75 CAPLUS COPYRIGHT 1999 ACS
AN 1998:806819 CAPLUS
DN 130:62055
TI BL172 antigen and cDNA and BL172 antibodies and methods of detecting urinary tract diseases
IN **Billing-Medel, Patricia A.**; **Cohen, Maurice**; **Colpitts, Tracey L.**; **Friedman, Paula N.**; **Gordon, Julian**; **Granados, Edward N.**; **Hodges, Steven C.**; **Klass, Michael R.**; Kratochvil, Jon D.; **Roberts-Rapp, Lisa**; **Russell, John C.**; **Stroupe, Stephen D.**; Yu, Hong
PA Abbott Laboratories, USA
SO PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9855656	A1	19981210	WO 98-US11693	19980605
	W: CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	US 97-869579		19970605		

AB A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as BL172 and transcribed from urinary tract tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or detg. the predisposition of an individual to diseases and conditions of the urinary tract, such as urinary tract cancer. Also provided are antibodies which specifically bind to BL172-encoded polypeptide or protein.

L20 ANSWER 5 OF 75 CAPLUS COPYRIGHT 1999 ACS
AN 1999:220096 CAPLUS
DN 130:247840
TI Reagents and methods useful for detecting diseases of the urinary tract
IN **Billing-Medel, Patricia A.**; **Cohen, Maurice**; **Friedman, Paula N.**; **Gordon, Julian**; **Hodges, Steven C.**; **Klass, Michael R.**; Kratochvil, Jon D.; Russell, Eric; **Stroupe, Stephen D.**
PA Abbott Laboratories, USA
SO PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9914372	A1	19990325	WO 98-US19362	19980915
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI US 97-58925		19970915		

AB Polypeptides and polynucleotides useful for detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or detg. the predisposition of an individual to diseases and conditions of the urinary tract, such as urinary cancer, are described. These sequences are derived from keratin/cytokeratin, CAS (cellular apoptosis susceptibility), or mat-8 polypeptides and polynucleotides and are up-regulated in urinary cancerous conditions but not expressed in the normal bladder. Also provided are antibodies which specifically bind to keratin/cytokeratin, CAS, or mat-8-encoded polypeptides or proteins, which mols. are useful for the therapeutic treatment of urinary tract diseases,

TI A marker gene for urinary tract disease and cancer and its diagnostic, therapeutic, and prognostic uses

IN **Billing-Medel, Patricia A.; Cohen, Maurice; Colpitts, Tracey L.; Friedman, Paula N.; Gordon, Julian; Granados, Edward N.; Hodges, Steven C.; Klass, Michael R.;** Kratochvil, Jon D.; **Russell, John C.; Stroupe, Stephen D.;** Yu, Hong

PA Abbott Laboratories, USA

SO PCT Int. Appl., 120 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9902734	A1	19990121	WO 98-US14210	19980708

W: CA, JP
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRAI US 97-889866 19970708

AB A set of contiguous and partially overlapping cDNA sequences from a gene designated BL210 that is transcribed in the urinary tract, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or detg. the predisposition of an individual to diseases and conditions of the urinary tract, such as bladder cancer. Antibodies specific for the BL210-encoded protein, and agonists or inhibitors which prevent action of the tissue-specific BL210 polypeptide, that may be useful for the therapeutic treatment of urinary tract diseases, tumors or metastases are also disclosed. The gene was identified as an EST cluster expressed in urinary tract tissue. Sequences were assembled into a full-length cDNA and a consensus sequence derived. Antigenic peptides derived from the consensus sequence were synthesized and used to immunize rabbits.